Five patients had pathogenic mutations in the RAS family, including two secondary AML patients with an HRAS and KRAS mutation, one AML patient with a KRAS mutation, one MDS patient with a KRAS mutation, and one MPN‐NOS patient with an NRAS mutation. Here, HRAS is linked to myeloproliferative neoplasm.